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Attention‐deficit hyperactivity disorder (ADHD) has consistently been associated
with substance use, but the nature of this association is not fully understood. To
inform intervention development and public health messages, a vital question is
whether there are causal pathways from ADHD to substance use and/or vice versa.
We applied bidirectional Mendelian randomization, using summary‐level data from
the largest available genome‐wide association studies (GWAS) on ADHD, smoking
(initiation, cigarettes per day, cessation, and a compound measure of lifetime
smoking), alcohol use (drinks per week, alcohol problems, and alcohol dependence),
cannabis use (initiation), and coffee consumption (cups per day). Genetic variants
robustly associated with the “exposure” were selected as instruments and identified
in the “outcome” GWAS. Effect estimates from individual genetic variants were com-
bined with inverse‐variance weighted regression and five sensitivity analyses
(weighted median, weighted mode, MR‐Egger, generalized summary data–based
MR, and Steiger filtering). We found evidence that liability to ADHD increases likeli-
hood of smoking initiation and heaviness of smoking among smokers, decreases like-
lihood of smoking cessation, and increases likelihood of cannabis initiation. There was
weak evidence that liability to ADHD increases alcohol dependence risk but not
drinks per week or alcohol problems. In the other direction, there was weak evidence
that smoking initiation increases ADHD risk, but follow‐up analyses suggested a high
probability of horizontal pleiotropy. There was no clear evidence of causal pathways
between ADHD and coffee consumption. Our findings corroborate epidemiological
evidence, suggesting causal pathways from liability to ADHD to smoking, cannabis
use, and, tentatively, alcohol dependence. Further work is needed to explore the
exact mechanisms mediating these causal effects.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Individuals who have been diagnosed with attention‐deficit hyperac-
tivity disorder (ADHD) are more likely to be (heavy) substance users
than are those without ADHD.1 Around 5.9% to 7.1% of children
and adolescents and 5.0% of adults are thought to meet the diagnostic
criteria for ADHD,2 and genetic studies support the notion that a clin-
ical diagnosis represents the extreme end of a continuum of impulsivity
and/or attention problems in the general population.3,4 Both ADHD
diagnosis and higher levels of impulsivity and attention problems are
associated with higher levels of cigarette smoking,5,6 cannabis use,7,8
alcohol use,7,9 and caffeine consumption.10,11 The exact nature of
these associations is not fully understood, which hampers the develop-
ment of evidence‐based interventions and public health messages.
Several explanations have been posited as to why ADHD and sub-
stance use are correlated. First, there are risk factors that increase sus-
ceptibility to both. These could be environmental factors that have
been shown to be risk factors for ADHD and substance use, such as
trauma exposure or other adverse early life events,12,13 or these could
be genetic influences with pleiotropic effects on both ADHD and sub-
stance use. Family studies have shown that ADHD and substance use
are moderately to highly heritable and indicate shared genetic risk fac-
tors.14,15 Overlap in genetic risk has also been examined in recent
genome‐wide association studies (GWAS) of ADHD and substance
use.4,16-19 Substantial genetic correlations were found for ADHD with
ever versus never smoking (rg = .48, P = 4.3e−16), number of ciga-
rettes smoked per day (rg = .45, P = 1.1e−05), alcohol dependence
(rg = .44, P = 4.2e−06), and cannabis initiation (rg = .16, P = 1.5e−04),
pointing to a common neurobiological aetiology. This is consistent
with research indicating that cognitive deficits such as impaired
response inhibition and working memory are important features of
both ADHD and substance abuse20,21 and that both ADHD and sub-
stance abuse can be considered forms of externalizing disorders.22
While a partial common neurobiological aetiology to ADHD and
substance use is therefore likely, environmental and genetic correla-
tions could also (partly) reflect causal effects of one on the other. If
variable X causes variable Y, it follows that any environmental or
genetic risk factor causing variable X will also be associated (indirectly)
with variable Y. The current literature has mostly focused on causal
pathways from ADHD to substance use, with longitudinal cohort stud-
ies showing that externalizing symptoms in early adolescence predict
onset of smoking and faster progression to daily smoking, and that
ADHDmedication reduces early‐onset smoking and alleviates smoking
withdrawal.5 For alcohol and cannabis, the evidence is less clear, withsome studies finding that ADHD symptoms only predict their use in
girls,23 and a recent twin study reporting no relation between ADHD
symptoms and alcohol or cannabis use.14 For caffeine, a relatively small
longitudinal study (n = 144) suggested reciprocal effects between caf-
feine consumption and ADHD symptoms during adolescence.10
There is tentative evidence that there may be causal effects in the
other direction (ie, substance use leading to an increase in ADHD
symptoms).24,25 In monozygotic twin pairs discordant for smoking,
the smoking twin scored higher on attention problems—a difference
that only appeared after smoking was initiated.24 For cannabis use,
the evidence is mixed. Low‐to‐moderate cannabis use in adolescents
seems to lead to a small increase in attention and academic problems,
which disappears following sustained abstinence.25 However, there is
no indication that cannabis use exacerbates ADHD‐related brain alter-
ations.26 With regard to alcohol use, binge‐pattern exposure during
development has been shown to cause attention deficits in mice,27
but there is no clear evidence for such effects in humans.
It is difficult to fully unravel the nature of the association between
ADHD and substance use with observational data because of bias due
to (unmeasured) confounding and reverse causality (ie, the outcome
affecting the exposure). Mendelian randomization (MR) is a method
to infer causality, which has recently gained much popularity. MR uses
genetic variants robustly associated with an exposure variable as an
instrument to test causal effects on an outcome variable.28,29 Because
genes are transmitted from parents to offspring randomly, genetic var-
iants that are inherited for a trait (eg, ADHD) should not be associated
with confounders such as social‐economic status. By using genetic
variants as instrumental variables, it is therefore possible to obtain less
biased results.
So far, one MR study found evidence for a causal effect of alcohol
use on attention problems and aggression in adolescents (but not on
delinquency, anxiety, or depression).30 Two other studies provided
evidence that genetic liability to ADHD, as well as higher extraversion,
has a causal effect on smoking initiation.31,32 A recent MR study found
that liability to ADHD leads to a higher risk of cannabis initiation, but
these analyses were based on summary‐level data of a cannabis
GWAS, which has recently been updated (with a much larger sample
size—n = 184 765 instead of n = 32 330). Moreover, potential causal
effects in the reverse direction were not adequately tested given that
the authors included all ADHD cases instead of just those diagnosed
in adulthood.33 Overall, existing MR studies are limited in that they
have primarily tested unidirectional effects only, included a narrow
focus on one specific substance use behaviour, and/or had limited sta-
tistical power.
TREUR ET AL. 3 of 11We therefore performed bidirectional MR using summary‐level
data of the largest available GWAS, investigating causal effects
between liability to ADHD and a broad spectrum of substance use
phenotypes. We applied five different sensitivity analyses more robust
to potential violation of the MR assumptions. Throughout the manu-
script, we refer to “liability to” a particular exposure (eg, liability to
ADHD). This is because the exposure estimates and the outcome esti-
mates for our analyses come from separate samples, and it is not pos-
sible to determine whether or not the individuals in the outcome
sample have actually experienced a particular exposure (eg, an ADHD
diagnosis).2 | MATERIALS AND METHODS
2.1 | Mendelian randomization
The rationale behind MR is that the random assortment of genetic var-
iants creates subgroups in the population, which roughly mimic treat-
ment groups from a randomized controlled trial. Outcomes are
compared between individuals in the “high genetic risk group” and
those in the “low genetic risk group” for a proposed exposure variable.
The method rests on three important assumptions, namely, that the
genetic variants used as instruments (1) strongly predict the exposure
variable—typically, the selected variants have been genome‐wide sig-
nificantly associated (P < 5e−08) with the exposure and replicated;
(2) are independent of confounding variables; and (3) do not affect
the outcome through an independent pathway, other than possible
causal effects via the exposure (Figure 1A). A potential threat to MRFIGURE 1 A, Illustration of the Mendelian randomization (MR) framewor
exposure (1), the instrument is not associated with (un)measured confound
through the exposure (3). B, Illustration of the MR design when using sum
association are taken from two separate GWAS (also known as “two‐samp
nucleotide polymorphismis horizontal pleiotropy, where the genetic variant used as an instru-
ment directly affects vulnerability to multiple phenotypes. This could
lead to violation of MR assumptions 2 and 3. To assess whether MR
assumptions may have been violated, we conducted various sensitivity
analyses described below.
We applied MR using summary‐level data (sometimes known as
“two‐sample MR”), which uses effect estimates of genetic variants
(single‐nucleotide polymorphisms [SNPs]) from large GWAS that have
been performed previously. In this approach, the SNP‐exposure asso-
ciation and the SNP‐outcome association estimates are taken from
two separate GWAS (Figure 1B). A major strength of this design is that
it takes advantage of large, well‐powered GWAS, without the need to
have information on both the exposure and the outcome in one single
sample. An additional assumption of this method is that the SNPs
identified as instruments based on their effect estimates in the expo-
sure GWAS also predict that exposure variable in the outcome
GWAS—this cannot be directly tested. To estimate the causal effect
of the exposure on the outcome, the SNP‐outcome association is
divided by the SNP‐exposure association for each SNP. The main
MR result is obtained by combining these ratios into an overall esti-
mate of a causal effect using inverse‐variance weighted (IVW) fixed‐
effect meta‐analysis (Figure 1B).292.2 | MR versus other causally informative designs
MR is inherently different from other causally informative designs
such as twin or family studies. While these methods use a priori
knowledge of genetic relatedness between family members to explaink and its main assumptions that the instrument is associated with the
ers (2), and the instrument does not influence the outcome other than
mary‐level data and the SNP‐exposure association and SNP‐outcome
le MR”). GWAS, genome‐wide association studies; SNP, single‐
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genotypes in (usually) unrelated individuals. Whereas twin and family
studies aim to correct for genetic (and shared environmental) differ-
ences in order to infer causality, MR exploits the genetic component
by using it as an instrument for causal inference. A comprehensive
review comparing all methods that use genetic data to strengthen
causal inference is available elsewhere.342.3 | Data
Summary‐level data of large GWAS were obtained for ADHD (clini-
cally diagnosed versus controls, n = 53 2934), smoking (initiation [ever
regularly smoked or ≥100 cigarettes during lifetime], n = 1 232 091;
cigarettes per day, n = 337 334; cessation [former versus current
smokers], n = 547 21917; lifetime smoking, n = 463 00335), alcohol
use (drinks per week, n = 941 28017; alcohol problems [AUDIT total
score: Alcohol Use Disorders Identification Test], n = 121 60419; alco-
hol dependence [clinically diagnosed versus controls], n = 46 56836),
cannabis use (initiation [ever used during lifetime], n = 184 76516),
and coffee consumption (cups per day, n = 91 46218). When smoking
initiation, cigarettes per day, smoking cessation, cannabis use initia-
tion,or alcohol drinks per week was the outcome in the MR analysis,
data of one of the included cohorts, 23andMe, were not available,
resulting in sample sizes of n = 632 783, n = 263 954, n = 312 821,
n = 162 082, and n = 537 341, respectively.
Lifetime smoking is a compound variable that captures smoking
initiation, duration, heaviness, and cessation, across middle to late
adulthood. As ADHD onset is expected to occur (long) before middle
to late adulthood, lifetime smoking was not appropriate to use as an
exposure and was only used as an outcome. In addition, cigarettes
per day and smoking cessation could not be used as exposures
because the GWAS that these are based on were performed in (for-
mer) smokers only. To perform an MR analysis with genetic variants
for cigarettes per day and smoking cessation as instruments, the
outcome GWAS (in this case ADHD) would have to be stratified
on smoking status, which was not possible with the summary data
we used.
When testing causal effects of liability to ADHD on substance
use, summary statistics from the complete ADHD GWAS containing
child, adolescent, and adult data were used. When testing causal
effects of substance use on ADHD, only adult data (ADHD diag-
nosed > 18 y) were used (n = 15 548) to ensure a plausible temporal
sequence of a potential causal effect (ie, substance use cannot logi-
cally have a causal effect on ADHD diagnosed in childhood). This is
crucial given that ADHD is generally a child‐onset disorder and the
onset of substance use is typically during adolescence or early adult-
hood. What we aim to test here is whether substance use causes
later development of or exacerbating of ADHD symptoms (resulting
in a diagnosis at adult age). There was no sample overlap of the
ADHD GWAS with the smoking, alcohol, and coffee GWAS.
Between the ADHD and the cannabis initiation GWAS, there was
very minimal overlap (<3%).2.4 | Main analysis
To assess causal effects of liability to ADHDon substance use, we iden-
tified independent SNPs that reached genome‐wide significance (P < 5e
−08) in the ADHD GWAS to use as genetic instruments. These same
SNPswere then identified in the substance use GWAS. To assess causal
effects in the other direction, we identified independent genome‐wide
significant SNPs in the different substance use GWAS as genetic
instruments, and then we identified those different sets of SNPs in
the ADHD GWAS. The analyses were conducted in R, using the two‐
sample MR package of MR‐Base, a database and analytical platform.372.5 | Sensitivity analyses
Besides IVW (Figure 1B), five additional MR methods were applied.
Each of these five methods can provide an unbiased estimate of the
true causal effect, provided that certain assumptions are met. While it
is not possible to know which of these methods' assumptions actually
hold, examining the combined results of all methods allows us to assess
the robustness of a causal finding. This practice of using multiple MR
methods to triangulate evidence has become increasingly important
now that MR has moved beyond more biological phenotypes (eg,
LDL‐cholesterol) and is increasingly used in the context of complex
traits such as ADHD and substance use, where detailed knowledge of
the exact biological function of the associated genes is lacking.38
First, we used weighted median regression, which provides an
unbiased estimate of the causal effect, even if <50% of the weight
of the genetic instrument comes from invalid instruments.39 Second,
we used weighted mode regression, which provides unbiased results
as long as the causal effect estimate that is most common among
the included SNPs comes from valid instruments and is thus consistent
with the true causal effect.40 Third, we used MR‐Egger regression,
which provides an unbiased estimate of the causal effect provided
that the strength of the genetic instrument (association between the
SNP and the exposure) does not correlate with the effect that same
instrument has on the outcome. This “InSIDE assumption” (Instrument
Strength Independent of Direct Effect) is a weaker assumption than
the assumption of no pleiotropy.41 However, MR‐Egger does rely on
the NOME (NO Measurement Error) assumption, and if this is vio-
lated, its results may be biased. Violation of the NOME assumption
can be assessed by the I2 statistic. An I2 value below 0.9 indicates con-
siderable risk of bias, which may still be corrected for with MR‐Egger
simulation extrapolation (SIMEX). An I2 value below 0.6 means that
MR‐Egger results (even with SIMEX) are unreliable. We report MR‐
Egger results when I2 > 0.9, report MR‐Egger SIMEX results when
I2 = 0.6‐0.9, and do not report MR‐Egger results when I2 < 0.6.42
Fourth, we used the generalized summary data–based MR (GSMR).43
This method achieves higher statistical power than other MR methods
by taking into account very low levels of linkage disequilibrium (LD)
between the included SNPs. The GSMR includes a filtering step that
identifies and removes SNPs considered outliers based on their effect
size (HEIDI filtering). MR‐Egger and GSMR were applied only when
TREUR ET AL. 5 of 11the genetic instruments contained 10 or more SNPs. Fifth, we used
Steiger filtering, which computes the amount of variance each SNP
explains in the exposure and in the outcome variable. In case of a true
causal effect of the exposure on the outcome, a SNP used as an
instrument should be more predictive of the exposure than the out-
come. If not (ie, the SNP is more predictive of the outcome than the
exposure), it might imply reverse causation.44 Steiger filtering was
used to exclude all SNPs that weremore predictive of the outcome than
the exposure, after whichMR analyseswere repeated. The latent causal
variable (LCV) model is a recent method with the potential to distin-
guish a genetic correlation from causation.45 While we conducted
LCV analyses, we report these in the supplemental material only
because (a) we aim to explicitly test bidirectional causality, which LCV
does not allow; and (b) for cigarettes smoked per day, smoking cessa-
tion, and lifetime smoking, LCV analysis is not appropriate because
we intended to only use them as outcome variables, and with LCV, it
is not possible to indicate which trait is the exposure or outcome.
For an additional indication of the robustness of our findings, we
inspected the Cochran Q statistic, which provides an estimate of het-
erogeneity between the effects of the individual genetic variants,46
and performed leave‐one‐out analyses, repeating the IVW analysis
after removing each of the SNPs one at a time.372.6 | Defining strength of evidence
We did not explicitly correct for multiple testing to avoid judging the
evidence based simply on an arbitrary threshold. Instead, we interpret
the evidence by looking at both the effect size and statistical evidence
for the main IVW result, combined with how consistent the results of
the sensitivity analyses are across multiple MR methods. Because of
their stricter assumptions, the sensitivity analyses have lower statisti-
cal power to identify a true causal effect. Thus, when the effect sizes
of the sensitivity analyses are of similar magnitude and direction, this
supports a causal interpretation, even if the statistical evidence for
an individual analytical approach is weaker than in the IVW analysis.3 | RESULTS
We found evidence for causal effects of liability to ADHD on smoking
initiation (IVW beta = .07, 95% CI, 0.03 to 0.11, P = 1.7e−05), ciga-
rettes smoked per day (IVW beta = .04, 95% CI, 0.02 to 0.06,
P = 0.006), smoking cessation (IVW beta = −.03, 95% CI, −0.05 to
−0.01, P = 0.005), and lifetime smoking (IVW beta = .07, 95% CI,
0.06 to 0.14, P = 1.4e−07). The weighted median and weighted mode
sensitivity analyses confirmed these findings, albeit with slightly
weaker statistical evidence for the latter (Table 1). For smoking initia-
tion, MR‐Egger did not show clear evidence for a causal effect, but
this may have been due to a lack of statistical power.41 The Egger
intercept did not indicate horizontal pleiotropy (intercept = 0.01,
95% CI, −0.01 to 0.02, P = 0.41, Table S2). For cigarettes smoked
per day and smoking cessation, MR‐Egger also did not confirm the
IVW findings, with weak evidence for horizontal pleiotropy (Eggerintercept = 0.01, 95% CI, 0.00 to 0.02, P = 0.068 and intercept = 0.01,
95% CI, 0.00 to 0.01, P = 0.089, respectively). The GSMR could not be
performed because there were too few SNPs (<10). Steiger filtering
showed that—with the exception of one SNP in the ADHD risk to
smoking initiation analysis—all SNPs were more predictive of the
exposure than of the outcome. Cochran Q statistic indicated heteroge-
neity of the effects of the included variants for the ADHD liability to
smoking initiation and ADHD liability to lifetime smoking analyses
(Table S3; Q = 34.44, P = 7.5e−05 and Q = 47.73, P = 2.9e−07, respec-
tively), while leave‐one‐out analyses gave no indication that the over-
all causal effect was driven by a particular SNP (Figure S1).
There was also considerable evidence that liability to ADHD caus-
ally increases risk of cannabis use initiation (IVW OR = 1.13, 95% CI,
1.02 to 1.25, P = 0.010). Weighted median, weighted mode, and
GSMR confirmed this finding, but with (slightly) weaker statistical evi-
dence. MR‐Egger was not reported due to a low I2 value (Table S4).
Steiger filtering did not identify any SNPs more predictive of the out-
come than of the exposure. There was weak evidence for heterogene-
ity in SNP effects for the ADHD liability to cannabis initiation analysis
(Q = 15.90, P = 0.069). Leave‐one‐out analyses did not suggest that
any individual SNPs were driving the overall effect.
There was no clear evidence for a causal effect of liability to
ADHD on alcohol drinks per week, alcohol problems, or coffee con-
sumption. While there was some weak evidence that liability to ADHD
causally influences alcohol dependence (IVW OR = 1.07, 95% CI, 1.01
to 1.14, P = 0.030), this effect was not consistent across the sensitivity
analyses. However, when we repeated these analyses using alcohol
intake frequency as the outcome measure in UK Biobank only—one
of the cohorts included in the much larger GWAS sample the main
analyses were based on—there was evidence for a causal effect
reflecting increased risk (IVW beta = .22, 95% CI, 0.04 to 0.40,
P = 0.013, Table S5). This is in line with recent findings that different
alcohol use behaviours can show distinct (directions of) genetic
associations.47
In the other direction, we found strong evidence for causal effects
of liability to smoking initiation on ADHD risk (IVW OR = 3.72, 95%
CI, 3.10 to 4.44, P = 2.9e−51). Weighted median, weighted mode,
MR‐Egger, and GSMR sensitivity analyses indicated similarly strong
evidence, albeit with smaller effect sizes (Table 2). The Egger intercept
did not indicate horizontal pleiotropy (intercept = 0.01, 95% CI, −0.01
to 0.03, P = 0.37). However, for this relationship, the I2 value was low
—0.60 (Table S4)—indicating that MR‐Egger was not reliable. Further-
more, Steiger filtering revealed that only 265 of the 346 smoking ini-
tiation SNPs (77%) were more predictive of the exposure, smoking,
than of the outcome, ADHD. When repeating the IVW and sensitivity
analyses with these SNPs only, the evidence for a causal effect was
still strong, but effect sizes were attenuated (Table S6). Cochran Q sta-
tistic provided no clear evidence for heterogeneity for the liability to
smoking initiation to ADHD risk analysis (Q = 373.84, P = 0.14), and
leave‐one‐out analyses did not indicate that the overall effects were
driven by a single SNP. As an additional sensitivity test, we repeated
the smoking initiation—ADHD analyses using ADHD symptoms in
childhood only, with one of the replication samples of the original
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TREUR ET AL. 7 of 11GWAS paper (<13 y; n = 17 66648). The degree to which smoking ini-
tiation SNPs predict ADHD childhood symptoms in such an MR anal-
ysis could reflect horizontal pleiotropy, since most individuals in this
age group will not have begun to smoke yet. We found strong evi-
dence for a causal effect (IVW beta = .28, 95% CI, 0.17 to 0.39;
Table S7)—although these effect estimates and the statistical evidence
were weaker than in the original analyses that restricted to adults.
Together with the results of Steiger filtering, this indicates that the
increasing effect of smoking initiation on ADHD risk is, at least in part,
due to horizontal pleiotropy.
There was no clear evidence for a causal effect of liability to can-
nabis use initiation, alcohol use, or coffee consumption on ADHD risk.
The results of LCV analyses indicated that smoking initiation and
alcohol dependence are genetically causal for ADHD, while for all
other relationships, there was no clear evidence of causal effects
(Table S8).4 | DISCUSSION
We find evidence, using the MR analyses of summary‐level data, for
causal effects of liability to ADHD on substance use risk, such that it
increases the odds of initiating smoking, smoking more cigarettes per
day among smokers, and finding it more difficult to quit, as well increas-
ing the odds of initiating cannabis use. There was some indication that
liability to ADHD increases alcohol dependence risk, but evidence for
that was weak. In the other direction, there was weak evidence that lia-
bility to smoking initiation increases (adult) ADHD risk. There was no
clear evidence of causal effects between liability to ADHD and coffee
consumption.
Our findings complement and confirm a large body of observa-
tional literature suggesting that individuals diagnosed with ADHD
are at a higher risk of initiating smoking, transitioning into regular
smoking, and being less able to quit.5 We also provide evidence for
a causal effect of liability to ADHD on risk of cannabis use, for which
the literature has so far been inconclusive.14,23 While previous obser-
vational studies may have been biased by (unmeasured) confounding,
our approach of using genetic variants as instrumental variables is
more robust to confounding and reverse causality. We were not able
to identify the exact mechanism of causation, but it seems plausible
that higher levels of impulsivity may lead individuals with ADHD liabil-
ity to try out cigarettes or cannabis without considering their possible
negative consequences.5,49 Another potential mechanism is “self‐
medication,” whereby a substance is used because of its (real or per-
ceived) positive effects on ADHD symptomatology—even though such
effects might not actually exist.50
Interestingly, therewas also evidence for causal effects of liability to
smoking on ADHD risk. This is in line with previous literature indicating
that smoking can have detrimental, long‐term effects on attention.24 It
has been hypothesized that nicotine inhaled through cigarette smoke
can affect the developing prefrontal cortex—involved in attention and
impulse control—during adolescence.51 It is important to note, however,
that the evidence we found for causal effects of smoking on ADHD riskwas much less robust than it was in the other direction. First of all, we
were not able to test causal effects of smoking heaviness or smoking
cessation on ADHD, which would have provided more compelling evi-
dence. Second, a considerable portion (23%) of the SNPs used as an
instrument for smoking initiation were in fact more predictive of the
outcome, ADHD, implying reverse causation. There is extensive
research showing that genetic influences on smoking initiation are
mediated via impulsivity‐related traits.5 This was confirmed by our find-
ings that the genetic instrument for smoking initiation also showed
strong evidence for a causal effect on ADHD symptoms in
children < 13 years (who would not yet have started smoking). Another
important point is that for the analyses of substance use to ADHD, we
used adult diagnosed ADHD as the outcome. This strengthened our
approach by ensuring the appropriate temporal sequence for a causal
effect in this direction. However, it might be that individuals with adult
diagnosed ADHD differ from those who were diagnosed during
childhood. A recent study assessed the neurodevelopmental profile of
individuals diagnosed with ADHD in adulthood and found that they
did not have a typical profile of neurodevelopmental impairment.52
Our results should therefore be replicated using other, continuous
measures of ADHD symptoms in adulthood. Preferably these would
be more “proximal” measures of attention problems and impulsivity,
obtained through cognitive performance tasks or (functional) brain
imaging.
We found some weak evidence for a causal effect of liability to
ADHD on alcohol dependence risk (based on a DSM diagnosis) but
no clear evidence for causal effects of liability to ADHD on drinks
per week or alcohol problems (based on the AUDIT self‐report sur-
vey). These findings are of particular interest because current evi-
dence on the mechanisms underlying associations between ADHD
and alcohol use is inconclusive.14,23 Given the very large and powerful
genetic data sets that our analyses are based on, one would expect
that a strong causal effect of ADHD on alcohol use would be convinc-
ingly shown, which was not the case given the weak evidence. The
fact that there was some indication of causality from ADHD liability
to alcohol dependence risk, but not for the other two alcohol mea-
sures, weakens the evidence further. However, it might be that ADHD
liability only affects serious manifestations of alcohol abuse—such that
it is clinically diagnosed—but not self‐reported consumption. Of all the
included GWAS data sets included in our study, alcohol dependence
was based on the smallest sample size (n = 46 568), and so it would
be good to attempt replication of this finding when bigger samples
become available. There was no clear evidence for causal effects
between liability to ADHD and coffee consumption, which would indi-
cate that observational correlations are the result of shared risk fac-
tors rather than causality.
Important strengths of this study include the very large and recent
samples that the analyses are based on, the variety of different
substance use phenotypes that were included, and the use of multiple
sensitivity analyses that each rely on distinctly different assumptions.
However, there are also limitations to consider. First, the genetic
instruments used in MR may vary in their strength (ie, the amount of
variance in the exposure variable that they explain). Stronger
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TREUR ET AL. 9 of 11instruments are more likely to identify a causal effect, which in theory
could explain why there was reasonable evidence for causality for
some relationships (eg, smoking to ADHD), but not for others (eg,
alcohol to ADHD). When looking at the predictive power of the instru-
ments, the differences were modest—for ADHD, all SNPs included in
the instrumental variable combined explained 0.5% to 0.7% of the var-
iance, for smoking initiation 2.4%, for cannabis initiation 0.2%, for
alcohol drinks per week 1.1%, for alcohol problems 0.3%, for alcohol
dependence 0.2%, and for coffee consumption 0.6% (the formula to
compute these numbers is described elsewhere16). However, the
power of these instruments to pick up effects on the outcomes also
depends on the sample size of the outcome samples. Second, we were
not able to apply all sensitivity analyses to all the tested relationships,
due to an insufficient number of robustly predictive SNPs for some of
the exposures. When even larger GWAS will become available,
identifying more SNPs, we will be able to examine these relationships
better. Third, and a more general limitation of MR, is that we cannot
correct for unmeasured familial confounding, such as “dynastic
effects,” which occur when parental genotypes have a direct effect
on offspring phenotypes. This could potentially be dealt with using
within‐family MR studies when large enough data sets become
available.53 Fourth, the nature of our study design did not allow us
to assess the role of ADHD medication status, which has previously
been shown to affect substance use.5 Fifth and final, the multiple
testing burden should be considered when interpreting our findings,
although this would not change our conclusions substantially, given
the strong statistical evidence for the main findings.
Overall, our findings add to the current literature by allowing
more robust conclusions on the causal nature of associations
between ADHD and substance use. We confirm previous evidence
from epidemiological studies that liability to ADHD increases the
odds of initiating smoking, smoking more heavily, and finding it more
difficult to quit.5 For cannabis and alcohol use, where epidemiologi-
cal studies were inconsistent, we show that liability to ADHD may
increase the odds of initiating cannabis use and, tentatively, of
developing alcohol dependence. This suggests that addressing
ADHD symptoms early on in life may not only decrease smoking ini-
tiation and progression but also cannabis initiation and the develop-
ment of alcohol dependence. To further inform preventive efforts,
future work should focus on the exact mechanisms through which
causal effects of liability to ADHD are mediated. One possibility
would be to perform an MR analysis for the different dimensions
of ADHD (attention problems vs impulsivity‐hyperactivity) sepa-
rately, if and when large enough GWAS for those phenotypes
become available. Another area of interest is cognitive training.
Efforts have been made to test whether training cognitive functions
such as inhibitory control, which is impaired in ADHD, can decrease
substance use. While for several health behaviours there is evidence
that stimulus‐specific inhibitory control training can be effective,54
the literature of its efficacy on smoking is still very scarce. Our find-
ing that smoking might causally increase ADHD risk should first be
replicated and followed up with different research methods and a
wider range of measures of ADHD symptoms. Such triangulation55will be essential to provide conclusive evidence on this, potentially
highly impactful, finding. For the relationships where there was no
indication of any causal effects—liability to ADHD and alcohol con-
sumption and coffee use—it seems that we can, tentatively, say that
the best approach for prevention would be to identify shared risk
factors that are modifiable, so as to decrease risk of ADHD as well
as alcohol and coffee consumption.
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